<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hu W</submitter><funding>Scholarship of Pujiang Talents in Shanghai</funding><funding>National Natural Science Foundation of China</funding><pagination>365-377</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11028344</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>68(3)</volume><pubmed_abstract>The interaction between programmed cell death protein 1 (PD-1) on activated T cells and its ligands on a target tumour may limit the capacity of chimeric antigen receptor (CAR) T cells to eradicate solid tumours. PD-1 blockade could potentially enhance CAR T cell function. Here, we show that mesothelin is overexpressed in human triple-negative breast cancer cells and can be targeted by CAR T cells. To overcome the suppressive effect of PD-1 on CAR T cells, we utilized CRISPR/Cas9 ribonucleoprotein-mediated editing to disrupt the programmed cell death-1 (PD-1) gene locus in human primary T cells, resulting in a significantly reduced PD-1&lt;sup>hi&lt;/sup> population. This reduction had little effect on CAR T cell proliferation but strongly augmented CAR T cell cytokine production and cytotoxicit</pubmed_abstract><journal>Cancer immunology, immunotherapy : CII</journal><pubmed_title>CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions.</pubmed_title><pmcid>PMC11028344</pmcid><funding_grant_id>14PJ1405600</funding_grant_id><funding_grant_id>81402542</funding_grant_id><pubmed_authors>Li G</pubmed_authors><pubmed_authors>Cai Q</pubmed_authors><pubmed_authors>Zi Z</pubmed_authors><pubmed_authors>Hu W</pubmed_authors><pubmed_authors>Shao K</pubmed_authors><pubmed_authors>Ma X</pubmed_authors><pubmed_authors>Wei F</pubmed_authors><pubmed_authors>Jin Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions.</name><description>The interaction between programmed cell death protein 1 (PD-1) on activated T cells and its ligands on a target tumour may limit the capacity of chimeric antigen receptor (CAR) T cells to eradicate solid tumours. PD-1 blockade could potentially enhance CAR T cell function. Here, we show that mesothelin is overexpressed in human triple-negative breast cancer cells and can be targeted by CAR T cells. To overcome the suppressive effect of PD-1 on CAR T cells, we utilized CRISPR/Cas9 ribonucleoprotein-mediated editing to disrupt the programmed cell death-1 (PD-1) gene locus in human primary T cells, resulting in a significantly reduced PD-1&lt;sup>hi&lt;/sup> population. This reduction had little effect on CAR T cell proliferation but strongly augmented CAR T cell cytokine production and cytotoxicit</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Mar</publication><modification>2025-04-22T16:45:04.843Z</modification><creation>2025-04-06T01:50:16.302Z</creation></dates><accession>S-EPMC11028344</accession><cross_references><pubmed>30523370</pubmed><doi>10.1007/s00262-018-2281-2</doi></cross_references></HashMap>